Disease Detail

Filtering

  • Case insensitive filtering will display rows where any text in any cell matches the filter term
  • Simple literal full or partial string matches
  • Separate multiple filter terms with a spaces, order doesn't matter (a b c and c b a are equivalent )
  • Filtering will only apply to rows that are already loaded on the page, filtering has no impact on query parameters
  • Use quotes to match a longer phrase which contains spaces "mtor c1483f"

Sorting

  • Generally, the default sort order for tables is set to be first column ascending, however, specific tables may set a different default sort order.
  • Click on any column header arrows to sort by that column
  • Hold down the Shift key and click multiple columns to sort by more than one column, be sure to set ascending or descending order for a given column, before moving on to the next column.

Molecular Profile Therapy Indication/Tumor Type Response Type Profile Response Detail
ETV6-NTRK3 Entrectinib salivary gland cancer predicted - sensitive detail...
ERBB2 positive DS-8201a salivary gland cancer predicted - sensitive detail...
ETV6-NTRK3 Crizotinib salivary gland cancer predicted - sensitive detail...
ERBB2 amp Pertuzumab + Trastuzumab salivary gland cancer predicted - sensitive detail...
ERBB2 over exp Pertuzumab + Trastuzumab salivary gland cancer predicted - sensitive detail...
Clinical Trial Phase Therapies Title Recruitment Status
NCT01316757 Phase II Carboplatin + Cetuximab + Erlotinib + Paclitaxel Carboplatin, Paclitaxel, Cetuximab, and Erlotinib Hydrochloride in Treating Patients With Metastatic or Recurrent Head and Neck Squamous Cell Cancer Completed
NCT02091141 Phase II Erlotinib Alectinib Cobimetinib + Vemurafenib Pertuzumab + Trastuzumab Vismodegib Atezolizumab My Pathway: A Study Evaluating Herceptin/Perjeta, Tarceva, Zelboraf/Cotellic, Erivedge, Alecensa, and Tecentriq Treatment Targeted Against Certain Molecular Alterations in Participants With Advanced Solid Tumors Recruiting
NCT02538510 Phase Ib/II Pembrolizumab + Vorinostat Pembrolizumab and Vorinostat in Treating Patients With Recurrent Squamous Cell Head and Neck Cancer and Salivary Gland Cancer That Is Metastatic and/or Cannot Be Removed by Surgery Active, not recruiting
NCT02576431 Phase II Larotrectinib A Study to Test the Effect of the Drug Larotrectinib in Adults and Children With NTRK-fusion Positive Solid Tumors (NAVIGATE) Recruiting
NCT02628067 Phase II Pembrolizumab Study of Pembrolizumab (MK-3475) in Participants With Advanced Solid Tumors (MK-3475-158/KEYNOTE-158) Recruiting
NCT02636036 Phase I Enadenotucirev + Pembrolizumab Study of Enadenotucirev and Pembrolizumab in Subjects With Metastatic or Advanced Epithelial Tumors Recruiting
NCT02749903 Phase II Enzalutamide Enzalutamide for Patients With Androgen Receptor Positive Salivary Cancers Active, not recruiting
NCT02795156 Phase II Cabozantinib Afatinib Regorafenib Study to Assess the Activity of Molecularly Matched Targeted Therapies in Select Tumor Types Based on Genomic Alterations Recruiting
NCT03172624 Phase II Ipilimumab + Nivolumab Study of Nivolumab Plus Ipilimumab in Patients With Salivary Gland Cancer Recruiting
NCT03319628 Phase I XMT-1536 First-in-Human Study of XMT-1536 in Cancers Likely to Express NaPi2b Recruiting
NCT03360890 Phase II Docetaxel + Pembrolizumab Synergy of Pembrolizumab Anti-PD-1 Immunotherapy With Chemotherapy for Poorly Chemo-responsive Thyroid and Salivary Gland Tumors Recruiting
NCT03781986 Phase Ib/II APG-115 APG-115 + Carboplatin A Phase I/II Trial of APG-115 in Patients With Salivary Gland Carcinoma Not yet recruiting